IRIS
SALADINI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.707
EU - Europa 5.274
AS - Asia 2.184
SA - Sud America 448
AF - Africa 42
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.660
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.628
RU - Federazione Russa 1.292
GB - Regno Unito 1.162
SG - Singapore 723
IT - Italia 709
CN - Cina 703
IE - Irlanda 689
BR - Brasile 394
SE - Svezia 385
DE - Germania 270
HK - Hong Kong 228
UA - Ucraina 212
FR - Francia 190
VN - Vietnam 147
FI - Finlandia 109
KR - Corea 99
IN - India 98
ES - Italia 91
CA - Canada 40
BE - Belgio 37
NL - Olanda 33
BD - Bangladesh 29
TR - Turchia 29
JP - Giappone 25
MX - Messico 24
AR - Argentina 23
PL - Polonia 23
LT - Lituania 13
ZA - Sudafrica 13
AT - Austria 12
CZ - Repubblica Ceca 12
IR - Iran 12
EC - Ecuador 11
IQ - Iraq 11
KZ - Kazakistan 10
UZ - Uzbekistan 10
GR - Grecia 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
ID - Indonesia 8
SK - Slovacchia (Repubblica Slovacca) 6
EE - Estonia 5
JM - Giamaica 5
PK - Pakistan 5
SA - Arabia Saudita 5
VE - Venezuela 5
CO - Colombia 4
DO - Repubblica Dominicana 4
LV - Lettonia 4
MA - Marocco 4
NP - Nepal 4
PY - Paraguay 4
AL - Albania 3
AU - Australia 3
BH - Bahrain 3
BO - Bolivia 3
ET - Etiopia 3
IL - Israele 3
KE - Kenya 3
OM - Oman 3
PA - Panama 3
TN - Tunisia 3
AZ - Azerbaigian 2
BW - Botswana 2
CI - Costa d'Avorio 2
DZ - Algeria 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
MY - Malesia 2
PE - Perù 2
PT - Portogallo 2
TH - Thailandia 2
TM - Turkmenistan 2
AM - Armenia 1
AO - Angola 1
BY - Bielorussia 1
CL - Cile 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
LB - Libano 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SY - Repubblica araba siriana 1
YE - Yemen 1
Totale 13.660
Salva come PNG Salva come JPEG
Città #
Southend 1.017
Dallas 852
Dublin 685
Fairfield 627
Ashburn 414
Singapore 395
Chandler 391
Moscow 357
Santa Clara 301
Woodbridge 270
Beijing 237
Siena 236
Seattle 228
Hong Kong 225
Cambridge 224
Ann Arbor 213
Houston 210
Wilmington 200
Jacksonville 178
Munich 117
Princeton 111
New York 100
Seoul 96
Hefei 85
Los Angeles 81
Málaga 66
Rome 57
Milan 53
Helsinki 48
Nanjing 47
Ho Chi Minh City 45
San Mateo 44
Boardman 42
São Paulo 40
Bengaluru 36
Shanghai 36
Dong Ket 33
Buffalo 32
Brussels 31
The Dalles 31
San Diego 30
Dearborn 27
Hanoi 27
Council Bluffs 26
Hangzhou 25
Portsmouth 22
Columbus 21
London 21
Redondo Beach 21
Turku 20
Menlo Park 19
Nanchang 19
Tokyo 19
Warsaw 18
Atlanta 16
Montreal 16
Chennai 15
Denver 15
Phoenix 15
Nuremberg 14
Redwood City 14
Stockholm 14
Toronto 14
Fremont 13
Mexico City 13
Shenyang 13
Düsseldorf 12
Frankfurt am Main 12
Izmir 12
San Francisco 12
Amsterdam 11
Belo Horizonte 11
Chicago 11
Hebei 11
Lappeenranta 11
Mumbai 11
Boston 10
Brasília 10
Brooklyn 10
Lancaster 10
Lauterbourg 10
Manchester 10
North Bergen 10
Norwalk 10
Tashkent 10
Tianjin 10
Changsha 9
Rio de Janeiro 9
Astana 8
Florence 8
Guangzhou 8
Jinan 8
Johannesburg 8
Poplar 8
Vienna 8
Ankara 7
Brno 7
Espoo 7
Jiaxing 7
Kunming 7
Totale 9.301
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 300
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 290
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 283
A novel methodology for large-scale phylogeny partition 278
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 277
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 277
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 270
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 264
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 257
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 252
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 252
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 243
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 241
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 236
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 234
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 231
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 229
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 228
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 225
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 224
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 223
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 222
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 219
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 218
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 218
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 217
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 216
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 214
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 213
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 213
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 212
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 208
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors 202
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 199
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 198
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 194
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 184
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 179
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 178
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 175
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 173
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 167
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 166
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 165
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 157
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 156
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 155
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 145
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 140
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects 138
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 137
Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 133
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 132
null 129
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 122
null 121
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 120
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 119
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 116
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 116
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 115
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 114
null 114
null 114
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 114
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 112
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 105
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 103
Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of HIV-1 unique recombinant forms 100
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes 99
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 91
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 83
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 78
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 75
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 74
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance 71
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 69
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 66
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 52
HIV-1 nucleocapsid inhibitors 49
Identification of a possible ancestor of the subtype A1 HIV type 1 variant circulating in the former Soviet Union (Aids Research and Human Retroviruses) 37
Molecular Epidemiology of HIV-1 in Eastern Europe and Russia 33
null 32
Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia 11
Totale 13.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021930 0 0 0 0 0 157 150 180 109 159 71 104
2021/20221.137 68 130 82 117 78 50 63 54 71 109 114 201
2022/20231.326 72 186 143 155 129 236 69 95 96 79 43 23
2023/20241.061 33 24 75 65 15 302 376 31 4 18 25 93
2024/20252.279 50 94 294 115 282 171 78 142 206 114 236 497
2025/20264.003 402 746 757 776 1.259 63 0 0 0 0 0 0
Totale 13.911